Liquidia (LQDA) Competitors

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 25.6% of Liquidia shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Jazz Pharmaceuticals presently has a consensus target price of $291.15, suggesting a potential upside of 25.29%. Liquidia has a consensus target price of $98.08, suggesting a potential upside of 195.40%. Given Liquidia's higher possible upside, analysts plainly believe Liquidia is more favorable than Jazz Pharmaceuticals.

Jazz Pharmaceuticals has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

In the previous week, Liquidia had 1 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 15 mentions for Liquidia and 14 mentions for Jazz Pharmaceuticals. Liquidia's average media sentiment score of 0.72 beat Jazz Pharmaceuticals' score of 0.25 indicating that Liquidia is being referred to more favorably in the news media.

Liquidia has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Liquidia has a net margin of 30.74% compared to Jazz Pharmaceuticals' net margin of 20.45%. Liquidia's return on equity of 149.65% beat Jazz Pharmaceuticals' return on equity.

Liquidia has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

64.5% of Liquidia shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Liquidia has a net margin of 30.74% compared to Neurocrine Biosciences' net margin of 20.91%. Liquidia's return on equity of 149.65% beat Neurocrine Biosciences' return on equity.

Liquidia presently has a consensus price target of $98.08, indicating a potential upside of 195.40%. Neurocrine Biosciences has a consensus price target of $202.73, indicating a potential upside of 42.65%. Given Liquidia's higher possible upside, equities analysts clearly believe Liquidia is more favorable than Neurocrine Biosciences.

Neurocrine Biosciences has higher revenue and earnings than Liquidia. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

In the previous week, Liquidia had 3 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 15 mentions for Liquidia and 12 mentions for Neurocrine Biosciences. Liquidia's average media sentiment score of 0.72 beat Neurocrine Biosciences' score of 0.08 indicating that Liquidia is being referred to more favorably in the media.

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 25.6% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Liquidia had 9 more articles in the media than Corcept Therapeutics. MarketBeat recorded 15 mentions for Liquidia and 6 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.96 beat Liquidia's score of 0.72 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Corcept Therapeutics has higher revenue and earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Corcept Therapeutics presently has a consensus target price of $138.17, indicating a potential upside of 19.35%. Liquidia has a consensus target price of $98.08, indicating a potential upside of 195.40%. Given Liquidia's higher possible upside, analysts clearly believe Liquidia is more favorable than Corcept Therapeutics.

Corcept Therapeutics has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Liquidia has a net margin of 30.74% compared to Corcept Therapeutics' net margin of 6.52%. Liquidia's return on equity of 149.65% beat Corcept Therapeutics' return on equity.

Liquidia has a net margin of 30.74% compared to Elanco Animal Health's net margin of -3.96%. Liquidia's return on equity of 149.65% beat Elanco Animal Health's return on equity.

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Elanco Animal Health has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market. Comparatively, Liquidia has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Liquidia has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

In the previous week, Liquidia had 11 more articles in the media than Elanco Animal Health. MarketBeat recorded 15 mentions for Liquidia and 4 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.75 beat Liquidia's score of 0.72 indicating that Elanco Animal Health is being referred to more favorably in the media.

Elanco Animal Health presently has a consensus target price of $29.70, suggesting a potential upside of 31.04%. Liquidia has a consensus target price of $98.08, suggesting a potential upside of 195.40%. Given Liquidia's higher possible upside, analysts clearly believe Liquidia is more favorable than Elanco Animal Health.